Antibody Repertoire Analysis of Hepatitis C Virus Infections Identifies Immune Signatures Associated With Spontaneous Clearance

• Main Authors: Sivan Eliyahu, Oz Sharabi, Shiri Elmedvi, Reut Timor, Ateret Davidovich, Francois Vigneault, Chris Clouser, Ronen Hope, Assy Nimer, Marius Braun, Yaacov Y. Weiss, Pazit Polak, Gur Yaari, Meital Gal-Tanamy
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2018-12-01
• Series: Frontiers in Immunology
• Subjects: hepatitis C virus; antibody repertoire; neutralizing antibodies; infectious disease; immune signature
• Online Access: https://www.frontiersin.org/article/10.3389/fimmu.2018.03004/full

Hepatitis C virus (HCV) is a major public health concern, with over 70 million people infected worldwide, who are at risk for developing life-threatening liver disease. No vaccine is available, and immunity against the virus is not well-understood. Following the acute stage, HCV usually causes chronic infections. However, ~30% of infected individuals spontaneously clear the virus. Therefore, using HCV as a model for comparing immune responses between spontaneous clearer (SC) and chronically infected (CI) individuals may empower the identification of mechanisms governing viral infection outcomes. Here, we provide the first in-depth analysis of adaptive immune receptor repertoires in individuals with current or past HCV infection. We demonstrate that SC individuals, in contrast to CI patients, develop clusters of antibodies with distinct properties. These antibodies' characteristics were used in a machine learning framework to accurately predict infection outcome. Using combinatorial antibody phage display library technology, we identified HCV-specific antibody sequences. By integrating these data with the repertoire analysis, we constructed two antibodies characterized by high neutralization breadth, which are associated with clearance. This study provides insight into the nature of effective immune response against HCV and demonstrates an innovative approach for constructing antibodies correlating with successful infection clearance. It may have clinical implications for prognosis of the future status of infection, and the design of effective immunotherapies and a vaccine for HCV.